Moderna's (NASDAQ:MRNA) vaccine is successfully helping people avoid the coronavirus. The billion-dollar product has demonstrated more than 90% efficacy in adults. And new data show it's 100% effective in teens. But Moderna faces one big challenge that could wreak havoc on how well its vaccine protects the population. And that's the rapid emergence of variants.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,